ANI Pharmaceuticals, Inc.

Total Valuation

ANI Pharmaceuticals, Inc. carries a market capitalization of 1.60B, placing it among publicly traded companies globally. Its enterprise value stands at 2.14B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

ANI Pharmaceuticals, Inc. currently has 22.97M shares outstanding.

Valuation Ratios

ANI Pharmaceuticals, Inc. trades at a trailing price-to-earnings ratio of 15.88. The price-to-sales ratio is 1.75, and the price-to-book ratio stands at 3.18.

Enterprise Valuation

On an enterprise value basis, ANI Pharmaceuticals, Inc. trades at an EV/EBITDA multiple of 9.88 and an EV/FCF ratio of 9.54. The EV/Sales ratio of 2.18 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 16.37 provides insight into valuation relative to core operating earnings.

Financial Position

ANI Pharmaceuticals, Inc. maintains a current ratio of 2.91, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 102.22, indicating elevated leverage, while an interest coverage ratio of 13.08 demonstrates strong ability to service its debt obligations.

Financial Efficiency

ANI Pharmaceuticals, Inc. posts a return on equity of 20.88 and a return on invested capital of 9.11.

Taxes

Over the trailing twelve months, ANI Pharmaceuticals, Inc. has paid 34.29M in income taxes, reflecting an effective tax rate of 24.04.

Stock Price Statistics

ANI Pharmaceuticals, Inc.'s stock has declined approximately -28.96468% over the past 52 weeks. The 50-day moving average sits at 77.56, while the 200-day moving average is 79.14.

Income Statement

Over the trailing twelve months, ANI Pharmaceuticals, Inc. generated 978.38M in revenue and converted that into 108.31M in net income, yielding earnings per share of 5.02. EBITDA reached 216.31M, while operating income came in at 130.50M.

Balance Sheet

ANI Pharmaceuticals, Inc. holds 375.84M in cash and equivalents against 610.49M in total debt, resulting in a net debt position of 250.28M. Total book value stands at 597.21M, with working capital of 541.78M providing operational flexibility.

Cash Flow

ANI Pharmaceuticals, Inc. produced 189.47M in operating cash flow over the past twelve months. After subtracting -21.94M in capital expenditures, free cash flow totaled 167.52M - equivalent to 8.09 per share.

Margins

ANI Pharmaceuticals, Inc. operates with a gross margin of 60.40, reflecting its pricing power and cost economics. The operating margin of 13.34 and net profit margin of 11.07 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

ANI Pharmaceuticals, Inc.'s most recent stock split took place on July 18, 2013 with a 6:1 split ratio.

Scores

ANI Pharmaceuticals, Inc. posts an Altman Z-Score of 3.41, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.